Prognostic factors in advanced non-small cell lung cancer: Elevated serum levels of neuron specific enolase indicate poor prognosis

Japanese Journal of Clinical Oncology

Volumn 30, Issue 12, 2000, Pages 534-541

  Maeda, Tadashi ^a   Ueoka, Hiroshi ^a   Tabata, Masahiro ^a   Kiura, Katsuyuki ^a   Shibayama, Takuo ^a   Gemba, Kenichi ^a   Takigawa, Nagio ^a   Hiraki, Akio ^a   Katayama, Hideki ^a   Harada, Mine ^a  

^a OKAYAMA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

Neuron specific enolase; Non small cell lung cancer; Prognostic factors; Recursive partitioning and amalgamation analysis

Indexed keywords

ALBUMIN; ANTINEOPLASTIC AGENT; BLEOMYCIN; CISPLATIN; CYCLOPHOSPHAMIDE; IFOSFAMIDE; METHOTREXATE; MITOMYCIN; NEURON SPECIFIC ENOLASE; PROCARBAZINE; VINCRISTINE; VINDESINE;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; BONE METASTASIS; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; ENZYME BLOOD LEVEL; HUMAN; LIVER METASTASIS; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PARTITION COEFFICIENT; PREDICTION; PROGNOSIS; RETROSPECTIVE STUDY; SURVIVAL RATE;

EID: 0034488459     PISSN: 03682811     EISSN: None     Source Type: Journal    
DOI: 10.1093/jjco/hyd139     Document Type: Article

References (23)

1. Chemotherapy vs supportive care in advanced non-small-cell lung cancer. Results of a meta-analysis of the literature
2. Meta-analysis of randomized trials of systemic chemotherapy versus supportive treatment in non-resectable non-small cell lung cancer
3. Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomized clinical trials
4. Revisions in the international system for staging lung cancer
5. Regression models and life tables
6. Regression and recursive partition strategies in the analysis of medical survival data
7. Combination chemotherapy of advanced lung cancer with cyclophosphamide, vincristine, methotrexate and procarbazine
8. A comparative study of cis-platinum and mitomycin C in patients with advanced non-small cell lung cancer
9. Phase II study of ifosfamide, cisplatin and vindesine combination in advanced non-small cell lung cancer
10. Toxicity and response criteria of the Eastern Cooperative Oncology Group
11. Reporting results of cancer treatment
12. Nonparametric estimation for incomplete observations
13. Evaluation of survival data and two new rank order statistics arising in its consideration
14. A generalized Wilcoxon test for comparing arbitrarily singlycensored samples
15. Survival determinants in extensive-stage non-small-cell lung cancer: The Southwest Oncology Group experience
16. Prognostic factors for survival in advanced non-small-cell lung cancer: Univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1052 patients
17. Prognostic factors in non-small cell lung cancer: A consensus report
18. Prognostic factors in non-small cell lung cancer
19. Clinical characterization of non-small-cell lung cancer tumor showing neuroendocrine differentiation features
20. The use of neuroendocrine immunoperoxidase markers to predict chemotherapy response in patients with non-small-cell lung cancer
21. Serum neuron specific enolase (NSE) levels in patients with non small cell lung cancer
22. Serum neuron specific enolase level as a prognostic factor in non-small cell lung cancer
23. Analysis of neuroendocrine markers, HER2 and CEA before and after chemotherapy in patients with stage IIIA non-small cell lung cancer: A Cancer and Leukemia Group B study